Zenith Drugs Limited (ZENITHDRUG)
📢 Recent Corporate Announcements
Zenith Drugs Limited has issued the notice for its 26th Annual General Meeting scheduled for September 29, 2026. Key special resolutions include enhancing the Board's borrowing powers under Section 180(1)(c) up to Rs 200 Cr (against current debt of Rs 55 Cr). The company is also seeking shareholder approval to revise executive remuneration up to Rs 84.00 lakh per annum each for Managing Director Sandeep Bhardwaj and Executive Director Bhupesh Soni for a 3-year period starting April 1, 2026.
- AGM scheduled for September 29, 2026; cut-off date for e-voting is September 22, 2026
- Special resolution proposed to set borrowing limit under Section 180(1)(c) up to Rs 200.00 Cr
- MD Sandeep Bhardwaj (21.38% stake) remuneration proposed up to Rs 84.00 lakh p.a. (vs Rs 48.00 lakh p.a. last drawn)
- ED Bhupesh Soni (20.18% stake) remuneration proposed up to Rs 84.00 lakh p.a. (vs Rs 67.80 lakh p.a. last drawn)
- Remote e-voting window open from September 26 to September 28, 2026
Zenith Drugs Limited announced the outcome of its board meeting held on September 05, 2026. The board approved the notice for the 26th Annual General Meeting (AGM) scheduled for September 29, 2026, via video conferencing. Additionally, M/s. Agrawal & Maheshwari, Practicing Company Secretaries, was re-appointed as the Secretarial Auditor for FY 2026-27, and Ms. Geetika Agrawal was appointed as the e-voting scrutinizer.
- 26th Annual General Meeting to be held on Tuesday, September 29, 2026, at 01:00 PM via VC/OAVM
- Appointed M/s. Agrawal & Maheshwari as Secretarial Auditor for FY 2026-27
- Ms. Geetika Agrawal appointed as Scrutinizer for the AGM e-voting process
- Board meeting conducted between 12:00 PM and 01:00 PM on September 05, 2026
Zenith Drugs Limited has approved the allotment of 16,09,050 convertible warrants to promoter group members at an issue price of ₹43.50 per warrant, aggregating up to ₹7.00 Cr. The company has received 25% upfront subscription consideration amounting to ₹1.75 Cr (₹1,74,98,421), with the balance 75% payable upon warrant conversion within 18 months. Upon full exercise, the allottees' collective holding will increase from 64.08% to 67.16%. Additionally, Executive Director Ajay Singh Dassundi has been re-designated as a Non-Executive Director effective August 27, 2026.
- Allotted 16,09,050 convertible warrants at ₹43.50 per warrant (FV ₹10 + premium ₹33.50) on preferential basis
- Total issue size of ₹7.00 Cr (~10% of current market cap of ₹70 Cr)
- Received ₹1.75 Cr upfront (25% consideration); balance 75% payable within 18 months
- Allotted equally (5,36,350 warrants each) to 3 promoters: Ajay Singh Dassundi, Sandeep Bhardwaj, and Bhupesh Soni
- Allottees' combined shareholding will rise from 64.08% to 67.16% upon full conversion
Zenith Drugs' Board has approved the allotment of 16,09,050 convertible warrants to three promoters at an issue price of Rs 43.50 per warrant on a preferential basis. The company received 25% upfront subscription money of Rs 1.75 Cr out of the total Rs 7.00 Cr issue size (~10.0% of market cap). Upon full exercise within 18 months, the combined stake of the three allottees will rise from 64.08% to 67.16%. In addition, Executive Director Ajay Singh Dassundi was re-designated as a Non-Executive Director effective August 27, 2026.
- Allotment of 16,09,050 convertible warrants approved at Rs 43.50 each (face value Rs 10 + premium Rs 33.50), aggregating to Rs 6,99,93,675
- Received 25% upfront application money of Rs 1,74,98,421 (~Rs 1.75 Cr), with 75% balance payable upon exercise within 18 months
- Allotment split equally among three promoters (Ajay Singh Dassundi, Sandeep Bhardwaj, Bhupesh Soni) at 5,36,350 warrants each
- Promoter group allottees' holding to expand from 64.08% (1.09 Cr shares) to 67.16% (1.26 Cr shares) post-conversion
- Ajay Singh Dassundi re-designated from Executive Director to Non-Executive (Non-Independent) Director w.e.f. August 27, 2026
Zenith Drugs Limited's board approved the allotment of 16,09,050 convertible warrants at ₹43.50 per warrant to three promoters, raising an aggregate of ₹7.00 Cr (~10% of market cap). The company received ₹1.75 Cr (25% upfront subscription consideration), with the remaining 75% payable upon warrant exercise within 18 months. Upon full conversion, the three promoters' combined shareholding will increase from 64.08% to 67.16%. Additionally, Executive Director Ajay Singh Dassundi has been re-designated as a Non-Executive (Non-Independent) Director effective August 27, 2026.
- Allotted 16,09,050 convertible warrants at an issue price of ₹43.50 each (face value ₹10 + premium ₹33.50)
- Total capital to be raised amounts to ₹6,99,93,675 (~₹7.00 Cr), with ₹1,74,98,421 (25%) received upfront
- Allotted equally (5,36,350 warrants each) across 3 promoters: Ajay Singh Dassundi, Sandeep Bhardwaj, and Bhupesh Soni
- Promoter group holding across the 3 allottees will expand from 64.08% to 67.16% post-full conversion
- Re-designated Ajay Singh Dassundi from Executive Director to Non-Executive Director w.e.f. August 27, 2026
Financial Performance
Revenue Growth by Segment
The company operates in a single primary business segment (Pharmaceuticals), making segment-wise growth reporting not applicable; however, revenue is described as moderate with a healthy historical compound annual growth rate.
Geographic Revenue Split
Domestic operations contribute the vast majority of revenue, with foreign exchange earnings reported at INR 34.39 Lacs (approximately 0.5% of net worth) for the financial year 2024-25.
Profitability Margins
Net profit for the half-year ended September 30, 2025, was INR 7.16 Cr, compared to INR 9.54 Cr for the full year ended March 31, 2025. Profitability is monitorable with a downward rating factor if it falls below 7%.
EBITDA Margin
Core profitability is supported by an operating profit before working capital changes of INR 7.87 Cr for H1 FY26 and INR 15.89 Cr for FY25; interest coverage is expected to remain adequate at over 3.5 times.
Capital Expenditure
The company has a planned debt-funded capital expenditure of INR 20.00 Cr for the development of a new product line in fiscal 2026, funded through INR 14.00 Cr in term debt and INR 6.00 Cr from internal accruals.
Credit Rating & Borrowing
The company maintains a comfortable financial risk profile with a net worth of INR 62.00 Cr as of March 31, 2024, and interest coverage ratios expected to stay above 3.5 times over the medium term.
Operational Drivers
Capacity Expansion
Planned expansion includes a new product line requiring INR 20.00 Cr investment in fiscal 2026 to increase manufacturing scale and product diversity.
Manufacturing Efficiency
Manufacturing efficiency is supported by a diverse product portfolio and a workforce of 182 permanent employees as of March 31, 2025.
Logistics & Distribution
The company leverages an extensive distribution and sales network built over two decades to market its branded generic drugs and ORS products.
Strategic Growth
Growth Strategy
Growth will be achieved through a INR 20.00 Cr capex plan for new product lines, leveraging the promoters' 20+ years of industry experience, and expanding the branded generic drug portfolio and third-party jobwork manufacturing.
Products & Services
The company manufactures and markets ORS (Oral Rehydration Salts), branded generic drugs, and various pharmaceutical formulations through third-party jobwork and government institutional business.
Brand Portfolio
Zenith Drugs
New Products/Services
A new product line is under development with a planned investment of INR 20.00 Cr scheduled for fiscal 2026.
Market Expansion
Expansion plans target increased reach in branded generics and institutional business, supported by a net worth expected to exceed INR 67.00 Cr by March 31, 2025.
External Factors
Industry Trends
The pharmaceutical industry is evolving with high regulatory oversight from agencies like CDSCO and NPPA, with a trend toward branded generics and institutional supply contracts.
Competitive Landscape
The landscape is characterized by intense competition from large-scale formulation manufacturers with integrated operations.
Competitive Moat
The moat is based on the promoters' 20-year industry experience and established client relationships, which are sustainable but challenged by the lack of R&D investment and intense pricing competition.
Macro Economic Sensitivity
The company is sensitive to regulatory shifts in the pharmaceutical sector and interest rate changes due to its INR 14.00 Cr planned debt for capex.
Regulatory & Governance
Industry Regulations
Operations are strictly governed by the Drugs and Cosmetics Act 1940, Drugs (Prices Control) Order 2013, and the Narcotic Drugs and Psychotropic Substances Act 1985.
Taxation Policy Impact
Current tax expense for the half-year ended September 30, 2025, was INR 2.37 Cr.
Legal Contingencies
The company reported no material weaknesses in internal financial controls; specific values for pending court cases are not disclosed in the provided summaries.
Risk Analysis
Key Uncertainties
The primary uncertainty involves the successful execution and ramp-up of the INR 20.00 Cr debt-funded capex and its impact on the capital structure if revenue growth does not follow.
Third Party Dependencies
The company relies on merchant dealers for exports and third-party jobwork manufacturing for a portion of its revenue.
Technology Obsolescence Risk
The company reported zero R&D expenditure, which may pose a long-term risk of technology or product obsolescence in a fast-evolving medical field.
Credit & Counterparty Risk
Credit risk is managed through internal controls, but the working capital-intensive nature of the business (GCA up to 350 days) remains a monitorable risk factor.
